ライフサイエンスコーパス: rehospitalization

1 ined endpoint of mortality and heart failure rehospitalization).

2 st-MI angina and long-term risk of unplanned rehospitalization.

3 nces, patients would rather avoid death than rehospitalization.

4 97) were associated with the highest risk of rehospitalization.

5 pact on all-cause mortality and the need for rehospitalization.

6 ) is associated with lower risk of death and rehospitalization.

7 of PVR on 1-year mortality and heart failure rehospitalization.

8 mortality, length of stay, and costs during rehospitalization.

9 the composite of all-cause mortality and HF rehospitalization.

10 e may adversely affect their outcomes during rehospitalization.

11 ignificant effect on short-term mortality or rehospitalization.

12 nical ventilation are at high risk for early rehospitalization.

13 ggest strategies for intervention to prevent rehospitalization.

14 eplacement (SAVR) for mortality, stroke, and rehospitalization.

15 n, chronic rejection, cancer, infection, and rehospitalization.

16 ge hospital rankings for 30-day mortality or rehospitalization.

17 rankings for 30-day all-cause mortality and rehospitalization.

18 e 9-item version (PHQ-9) to predict death or rehospitalization.

19 wer 30-day mortality, but had similar 30-day rehospitalization.

20 alized patients, and factors associated with rehospitalization.

21 es the association between ICD treatment and rehospitalization.

22 associated with the greatest hazard of early rehospitalization.

23 o (MOR) for in-hospital mortality and 30-day rehospitalization.

24 ng hospital discharge and the probability of rehospitalization.

25 ion rates have intensified efforts to reduce rehospitalization.

26 OR = 1.69; P = 0.032), but no HCE for 30-day rehospitalization.

27 nd for rates of cardiovascular mortality and rehospitalization.

28 ninvasive remote monitoring in predicting HF rehospitalization.

29 ital mortality, age at baseline, or costs of rehospitalization.

30 the hospital are at high risk for death and rehospitalization.

31 n lowering total bleeding and cardiovascular rehospitalization.

32 ominantly frail adults, but no difference in rehospitalization.

33 .5) when compared with patients without such rehospitalizations.

34 nctional status may help to reduce unplanned rehospitalizations.

35 atients was 7.6% for early and 4.6% for late rehospitalizations.

36 patients who are at high risk for unplanned rehospitalizations.

37 scharge from hospital and recovery and fewer rehospitalizations.

38 dex, may allow hospitals to reduce unplanned rehospitalizations.

39 ts assigned to VKA+SAPT experienced multiple rehospitalizations.

40 rointestinal bleeding, and cirrhosis-related rehospitalizations.

41 tality (23 +/- 3% vs. 36 +/- 3%; p = 0.001), rehospitalization (26 +/- 3% vs. 47 +/- 3%; p < 0.0001),

42 Over one quarter of all rehospitalizations (28.6% for early; 26.7% for late) inv

43 95% confidence interval, 0.82-0.95), 6-month rehospitalization (36.3% in 2006, 33.7% in 2010; adjuste

44 7% vs 57.2%, ARR 95%CI: -9.1% to -1.9%), and rehospitalizations (41.8% vs 45.8%, ARR 95%CI: -7.5% to

45 al cardiovascular events (4.5% versus 4.5%), rehospitalization (43% versus 49%), emergency department

46 6% vs 77.1%, ARR 95%CI: -8.5% to -2.4%), and rehospitalizations (47.4% vs 52.3%, ARR 95%CI: -8.0% to

47 to predict the risk of HF and cardiovascular rehospitalization 60 days after hospitalization for acut

48 The majority of unplanned rehospitalizations (72%) were for cardiovascular reasons

49 to examine the association between race and rehospitalization according to plasma renin activity (PR

50 (adjusted HR, 1.17 [95% CI, 1.05-1.30]) and rehospitalization (adjusted HR, 1.14 [95% CI, 1.07-1.22]

51 sociated with racial differences in risk for rehospitalization after acute heart failure.

52 tive, any unplanned inpatient or observation rehospitalization after acute myocardial infarction repr

53 and have individually been found to predict rehospitalization after admission for acute heart failur

54 n to better predict patients at low risk for rehospitalization after admission for acute HF.

55 response improves risk prediction for early rehospitalization after an admission for acute HF and ma

56 We sought to determine the frequency of rehospitalization after an ICU stay, outcomes for rehosp

57 Limited data suggest high rates of unplanned rehospitalization after endovascular and surgical revasc

58 orm using continuous data streams to predict rehospitalization after HF admission.

59 nd resource use but information on unplanned rehospitalization after injury admissions is scarce.

60 Early rehospitalization after kidney transplantation (KTx) is

61 pact of patient age on the risks of death or rehospitalization after primary prevention implantable c

62 Rehospitalizations after acute myocardial infarction for

63 re sensitive conditions compared with 23% of rehospitalizations after common acute medical conditions

64 ission rates, causes, and costs of unplanned rehospitalizations after peripheral arterial revasculari

65 ined 1- and 2-year cardiovascular (CV) death/rehospitalization (all p < 0.002) and all-cause death at

66 ease, an intensive care unit admission, or a rehospitalization (all P </= .04) compared with those wh

67 individual- and hospital-level predictors of rehospitalization among individuals with advanced cancer

68 brillators (ICD) and all-cause mortality and rehospitalization among patients undergoing initial ICD

69 vs usual care on mortality and heart failure rehospitalization among patients with acute heart failur

70 ccurrence of all bleeding and cardiovascular rehospitalizations among subjects on a novel oral antico

71 eding, repeat coronary procedures, death, or rehospitalization) among patients in these studies who w

72 ntervention on the composite end point of HF rehospitalization and cardiac death in this population.

73 Information on rehospitalization and death after HHC discharge is not a

74 ital is associated with a high risk of early rehospitalization and death.

75 reate a comprehensive dataset for mortality, rehospitalization and kidney allograft failure/rejection

76 acute heart failure patients at low risk for rehospitalization and mortality.

77 to assess factors associated with unplanned rehospitalization and tested for interactions among angi

78 Risk of rehospitalization and treatment failure (defined as psyc

79 e databases were linked to study the risk of rehospitalization and treatment failure from July 1, 200

80 verted mortality, utility loss, and costs of rehospitalization and/or further treatments for recurren

81 CI, 1.09-4.84) even after adjusting for both rehospitalizations and emergency department visits betwe

82 The number of rehospitalizations and emergency department visits were

83 e common, the overall fiscal impact of these rehospitalizations and their variability between hospita

84 ncluding need for renal replacement therapy, rehospitalization, and death, according to the incidence

85 end point composite of all-cause mortality, rehospitalization, and emergency department visits at 90

86 ns after myocardial infarction on mortality, rehospitalization, and functional decline in the frailes

87 Outcomes were 90-day death, rehospitalization, and functional decline.

88 tential HCE for length of stay (LOS), 30-day rehospitalization, and in-hospital mortality, adjusting

89 Hemoglobin levels and RBC transfusion, rehospitalization, and mortality events within 6 months

90 entions), healthcare utilization (ED visits, rehospitalizations, and expenditures), and heterogeneity

91 cohort, including intensive care admission, rehospitalizations, and self-reported recovery at follow

92 Early unplanned rehospitalizations are common after acute myocardial inf

93 ients with heart failure (HF), use of 30-day rehospitalization as a healthcare metric and increased p

94 imary outcomes were defined as mortality and rehospitalization as a result of HF.

95 Rates of death and rehospitalization, as well as the composite end point, w

96 results in lower rates of death, stroke, and rehospitalization at 1 year compared with surgical aorti

97 e rate of the composite of death, stroke, or rehospitalization at 1 year was significantly lower with

98 th increased risk of death and heart failure rehospitalization at 1 year.

99 omposite end point of mortality, stroke, and rehospitalization at 1 year.

100 es included all-cause mortality, stroke, and rehospitalization at 1 year.

101 d point was a composite of death, stroke, or rehospitalization at 1 year.

102 osite outcome of all-cause mortality and AHF rehospitalization at 180 days.

103 not associated with death alone and death or rehospitalization at 30 days.

104 -$2,877.88; P = 0.005), whereas survivors of rehospitalization at a different hospital had a modest i

105 We measured frequency of rehospitalization at a different hospital, mortality, le

106 the medical claims forms and records for all rehospitalizations at 233 US hospitals within 1 year of

107 The estimated 1-year rate of rehospitalization because of heart failure was 22.8%, si

108 outcome was the cumulative incidence of late rehospitalization (between 31 and 180 d).

109 y associated with greater risks of death and rehospitalization, but similar risks of procedural compl

110 le improved targeting of programs to prevent rehospitalizations, but obtaining such information direc

111 nificantly reduced the risk of mortality and rehospitalization caused by HF.

112 e to decompensated HF, and a major burden of rehospitalization caused by recurrent episodes of infect

113 number of rehospitalizations caused by respiratory problems, preva

114 e mortality, myocardial infarction (MI), and rehospitalization compared with a conservative invasive

115 associated with substantially lower risk of rehospitalization compared with equivalent oral formulat

116 ociated with greater survival and reduced HF rehospitalization compared with medical therapy alone.

117 gardless of age, women have a higher risk of rehospitalization compared with men over the first year

118 ienced adverse clinical outcomes of death or rehospitalization compared with those who remained free

119 py (SAPT) reduces bleeding or cardiovascular rehospitalizations compared with a vitamin K antagonist

120 ardial infarction, unstable angina requiring rehospitalization, coronary revascularization (>/=30 day

121 sity, low hemoglobin, gastroduodenal ulcers, rehospitalization, critical illness, thrombocytopenia, b

122 2,653 ICU patients, 79,960 had a first early rehospitalization (cumulative incidence, 16.2%) and an a

123 idence, 16.2%) and an additional 73,250 late rehospitalizations (cumulative incidence, 18.9%).

124 timated sex differences in the daily risk of rehospitalization/death 1 year after discharge from a po

125 ive incidence of cerebrovascular events, and rehospitalization due to cardiac reasons and acute heart

126 ve comparable mortality, MACCE, and rates of rehospitalization due to cardiac reasons at 1 year.

127 ecurrent major adverse cardiovascular event: rehospitalizations due to myocardial infarction (n = 4;

128 ients at low risk for the primary outcome of rehospitalization, emergency department visits, and mort

129 p between WHF and the composite end point of rehospitalization, emergency room visits for HF, and mor

130 509 death, 820 functional decline, and 1226 rehospitalization events.

131 point, a composite of all-cause mortality or rehospitalization for AHF at 180 days, occurred in 117 p

132 nt was a composite of all-cause mortality or rehospitalization for AHF at 180 days.

133 especified outcomes at 30 days were death or rehospitalization for any reason; death or rehospitaliza

134 tality (P=0.002) and cardiovascular death or rehospitalization for cardiovascular causes (P=0.001).

135 r rehospitalization for any reason; death or rehospitalization for cardiovascular or renal reasons; a

136 d points were all-cause death, nonfatal AMI, rehospitalization for evaluation of possible AMI, and co

137 ere associated with death alone and death or rehospitalization for heart failure (all tests, P<0.0001

138 6-1.17; P=0.270), and all-cause mortality or rehospitalization for heart failure (hazard ratio, 1.00;

139 ) and the combined endpoint of mortality and rehospitalization for heart failure (hazard ratio: 1.19

140 rdiac sensors have shown promise in reducing rehospitalization for heart failure (HF), but the effica

141 relative risk, 0.82; corrected P=0.002), and rehospitalization for heart failure (relative risk, 0.84

142 crease in overall or cardiovascular death or rehospitalization for heart failure after a mean follow-

143 Variables associated with mortality or rehospitalization for heart failure after multivariate a

144 pitalization, at 30-days and 12-months), and rehospitalization for heart failure and non-fatal AMI at

145 Rehospitalization for heart failure and pacemaker implan

146 Rehospitalization for heart failure occurred in 2 patien

147 dence of death from cardiovascular causes or rehospitalization for heart failure or renal failure at

148 analysis was the composite of (1) death; (2) rehospitalization for heart failure symptoms and valve p

149 all-cause stroke, myocardial infarction, or rehospitalization for heart failure was not different be

150 utcome (rank score of time to death, time to rehospitalization for heart failure, and change in NT-pr

151 es of all-cause death, cardiovascular death, rehospitalization for heart failure, and pacemaker impla

152 3 hierarchical tiers: time to death, time to rehospitalization for heart failure, and time-averaged p

153 failure during the initial hospitalization, rehospitalization for heart failure, or adverse left ven

154 Clinical outcomes included mortality and rehospitalization for heart failure.

155 ion were associated with 30-day mortality or rehospitalization for heart failure.

156 e primary end point was the rate of death or rehospitalization for heart failure.

157 t was a composite of all-cause mortality and rehospitalization for HF at 18 months.

158 The incidence of death or rehospitalization for HF at 24 weeks was 6%, 31%, and 30

159 moconcentration had a markedly lower risk of rehospitalization for HF in PROTECT (multivariable HR, 0

160 versus enalapril on cardiovascular death or rehospitalization for HF.

161 ffects of prolonged anakinra on peak Vo2 and rehospitalization for HF.

162 Similar results were found for rehospitalization for MI (cumulative incidence, 3.4% vs.

163 ated with a lower risk for cardiac death and rehospitalization for MI compared with a conservative in

164 Risk for cardiac death or rehospitalization for MI within 60 days of hospitalizati

165 Rehospitalization for myocardial infarction at 1 year oc

166 se or the composite of death from any cause, rehospitalization for myocardial infarction, or stent th

167 The composite of death from any cause, rehospitalization for myocardial infarction, or stent th

168 ular events, defined as all-cause mortality, rehospitalization for myocardial infarction, rehospitali

169 psis hospitalization that is not present for rehospitalization for nonsepsis diagnoses.

170 hrombosis, or unplanned revascularization or rehospitalization for progressive angina or unstable ang

171 outcomes for efficacy (all-cause mortality, rehospitalization for refractory ischemia/angina, myocar

172 Less surfactant-treated infants needed rehospitalization for respiratory problems after dischar

173 rehospitalization for myocardial infarction, rehospitalization for stroke, or repeat revascularizatio

174 between those who did and did not experience rehospitalization for UA or revascularization using a hi

175 fined as cardiac death, death, reinfarction, rehospitalization for unstable angina, repeat coronary r

176 er treated medically in the RYGB group and 2 rehospitalizations for dehydration in the LAGB group.

177 ratio, 1.10 [95% CI, 0.57-2.14]; P = .78) or rehospitalizations for heart failure (63 [41%] vs 50 [34

178 Previous studies have linked frequent rehospitalizations for heart failure (HF) and increased

179 Preventing rehospitalizations for patients with serious chronic ill

180 Rehospitalizations for recurrent congestion portend poor

181 e summary scores were worse in patients with rehospitalizations for UA (mean difference, -10.1; 95% c

182 irst year after acute myocardial infarction, rehospitalizations for UA and unplanned revascularizatio

183 ge between baseline and 1 year) and death or rehospitalization from 1 to 5 years were examined.

184 od clinical outcomes, including decreases in rehospitalization, functional improvements, and favorabl

185 resents a significant event; these unplanned rehospitalizations have not been well characterized.

186 ed with greater survival and freedom from HF rehospitalization (hazard ratio [HR]: 0.60; 95% confiden

187 ence interval, 0.60-0.92) and less all-cause rehospitalization (hazard ratio, 0.87; confidence interv

188 .04-1.09; P<0.001, respectively), as well as rehospitalization (hazard ratio, 1.07; confidence interv

189 s, women had a persistent 26% higher risk of rehospitalization (hazard ratio, 1.26; 95% confidence in

190 was most strongly associated with unplanned rehospitalization (hazard ratio, 1.49; 95% confidence in

191 rade 3 DD was a predictor of 1-year CV death/rehospitalization (hazard ratio: 2.73; 95% confidence in

192 t 30 days was protective for 1-year CV death/rehospitalizations (hazard ratio: 0.39; 95% confidence i

193 0-4.43; P = .005) and composite of mortality/rehospitalization (HR, 2.35; 95% CI, 1.52-3.62; P < .001

194 rhea may lead to dehydration, malabsorption, rehospitalization, immunosuppression, noncompliance, and

195 risk of all-cause and heart failure-specific rehospitalization in nonblack patients with increasing l

196 he association between RPM use and all-cause rehospitalization in patients enrolled in Medicare fee-f

197 mpared with men, women are at higher risk of rehospitalization in the first month after discharge for

198 The absolute risk reductions of COPD-related rehospitalization in the health coaching group were 7.5%

199 Women have an increased risk of rehospitalization in the immediate postdischarge period;

200 calculate hospitalization rates and to model rehospitalization in the year after diagnosis, accountin

201 g hospital discharge are estimated to reduce rehospitalizations in patients undergoing hemodialysis.

202 activity, prognostic biomarkers, and cardiac rehospitalizations in post-ACS patients.

203 in a prospective, 24-center US study who had rehospitalizations independently classified by experienc

204 Our primary outcome was unplanned rehospitalizations (inpatient or observation status) wit

205 The risk of rehospitalization is about 20% to 30% lower during long-

206 there was no stroke, myocardial infarction, rehospitalization, left ventricular outflow tract obstru

207 ormation about long-term mortality, rates of rehospitalization, long-term morbidity, comparative effe

208 practice and Medicare payment penalties for rehospitalization may have confounded the results.

209 ity of this low-cost noninvasive approach to rehospitalization mitigation should be further tested.

210 t-centered outcome measure that accounts for rehospitalization, mortality, and postdischarge care.

211 erm outcomes on the basis of 1-year risk for rehospitalization, mortality, or allograft failure/rejec

212 alculated the (1) time required for adjusted rehospitalization/mortality risks to decline 50% from ma

213 ed an emergency department visit (n = 96), a rehospitalization (n = 38), or both (n = 24).

214 nical efficacy (ie, survival free of stroke, rehospitalization, New York Heart Association 3/4, and d

215 Rehospitalization odds ratios were 1.00 (95% CI, 0.85-1.

216 se) was associated with lower odds of 30-day rehospitalization (odds ratio, 0.95; 95% confidence inte

217 Risk of rehospitalization of patients using RPM (n=9150, 60%) wa

218 ffer recurrent disease, which often requires rehospitalization of patients.

219 characteristics were associated with 30-day rehospitalization: older age, the number of hospital adm

220 blation, no differences in procedure-related rehospitalization or antiarrhythmic drug utilization wer

221 Risk for rehospitalization or death was higher for male patients

222 dow for recurrent clinical events, including rehospitalization or death.

223 outcome of time to first heart failure (HF) rehospitalization or death.

224 d ratio (HR) of risk factors associated with rehospitalization or death.

225 Randomization to UC + PAL did not affect rehospitalization or mortality.

226 Primary endpoint was 1-year mortality or HF rehospitalization or the composite.

227 ith any increased risk for 1-year mortality, rehospitalization, or allograft failure/rejection.

228 accompanied by a rise in subsequent RBC use, rehospitalization, or mortality within 6 months of hospi

229 d was associated with higher rates of death, rehospitalization, or stroke at 2 years compared with th

230 ore of 3-4), and the association with death, rehospitalization, or unscheduled medical visits through

231 se patients had lower 60-day rates of death, rehospitalization, or unscheduled visits (50%) compared

232 infarction, stroke, recurrent ischemia with rehospitalization, or urgent coronary revascularization

233 d quality of care and help to lower rates of rehospitalization overall and particularly among black a

234 of DD/grade 1 DD had reduced 1-year CV death/rehospitalization (p < 0.001) and increased 2-year survi

235 TAVR and adverse outcomes (death, p = 0.15; rehospitalization, p = 0.16), whereas AC after SAVR was

236 ssociated with lower risk of 30-day death or rehospitalization (per 10 patient increase: odds ratio,

237 and group 3=12.4%) and all-cause death plus rehospitalization potentially resulting from a cardiovas

238 ithin a disadvantaged U.S. neighborhood is a rehospitalization predictor of magnitude similar to chro

239 iation in hospital rates of 30-day unplanned rehospitalization ranged from 5.4% to 20.0%, with a medi

240 edicare and Medicaid-linked patients, the HF rehospitalization rate at 1 year was 35.1% (95% CI, 34.5

241 The 30-day rehospitalization rate did not vary significantly across

242 The 3-year all-cause rehospitalization rate in the Medicare population (n=15,

243 d 85% of neighborhoods, which had an average rehospitalization rate of 21%.

244 The overall 30-day rehospitalization rate was 21.2% (11959 of 56477 patient

245 0.33; log-rank P = .026), and reduced 30-day rehospitalization rates (16.9% vs 23.9%, P = .036).

246 fferences and factors associated with 1-year rehospitalization rates after AMI.

247 onary disease (COPD) exacerbations have high rehospitalization rates and reduced quality of life.

248 Rehospitalization rates for UA and unplanned revasculari

249 One-year crude all-cause rehospitalization rates for women were significantly hig

250 the most disadvantaged 15% of neighborhoods, rehospitalization rates increased from 22% to 27% with w

251 Rehospitalization rates were significantly associated wi

252 Rehospitalization rates were significantly lower after d

253 on costs but decreased mortality and reduced rehospitalization rates.

254 U and hospital stay, 6-month recurrence, and rehospitalization rates.

255 outcome was clinical failure, a composite of rehospitalization, re-initiation of antibiotics, or all-

256 admitted yearly to an ICU, the frequency of rehospitalizations (readmissions to the hospital after d

257 outcome was clinical failure, a composite of rehospitalization, reinitiation of antibiotics, or all-c

258 y mediating the relationship between sex and rehospitalization remain unexplored and are needed to re

259 he most disadvantaged neighborhoods having a rehospitalization risk (adjusted risk ratio, 1.09 [95% C

260 nding the determinants of sex differences in rehospitalization risk among conditions.

261 1-year angina frequency and 1-year unplanned rehospitalization stratified by race and sex among MI pa

262 haracteristics were strongly associated with rehospitalization, suggesting that identifying high-risk

263 ant age-sex interaction was found for 1-year rehospitalization, suggesting that the increased risk ap

264 nd treatment failure (defined as psychiatric rehospitalization, suicide attempt, discontinuation or s

265 o identify factors associated with unplanned rehospitalization, testing for whether race and sex modi

266 ost-MI angina frequency and 1-year unplanned rehospitalization to identify factors associated with un

267 interaction between age and ICD treatment on rehospitalization (two-sided posterior tail probability

268 ions of PHQ-2 and PHQ-9 with both, death and rehospitalization, univariable Cox regression models wer

269 We compared sex differences in rehospitalization using a Cox proportional hazards model

270 identified factors associated with unplanned rehospitalizations using multivariable logistic regressi

271 The adjusted daily risk of rehospitalization varied by admitting condition (hazard

272 The effects of treatment on rehospitalization varied significantly over time.

273 ction, right heart failure, arrhythmias, and rehospitalizations varied greatly.

274 gh the association of sex with daily risk of rehospitalization varies across conditions, women are at

275 noncardiac comorbidities, mortality, stroke, rehospitalization, vascular complications, bleeding comp

276 s at a different hospital, 13.7% died during rehospitalization versus 11.1% who died at the index hos

277 The burden of all-cause rehospitalization was comparable irrespective of the cat

278 increasing levels of PRA, while the risk of rehospitalization was relatively constant across levels

279 ted analyses, the composite of mortality and rehospitalization was similar for all subgroups.

280 The risk of psychiatric rehospitalization was the lowest during monotherapy with

281 tors most strongly associated with unplanned rehospitalization were baseline quality of life and depr

282 between neighborhood ADI grouping and 30-day rehospitalization were evaluated using multivariate logi

283 ar outcomes including mortality, stroke, and rehospitalization were evaluated using multivariate mode

284 Mortality and rehospitalization were examined using landmark analyses

285 Rates of 1-year unplanned rehospitalization were highest among black female patien

286 ompared with the VKA arm, but other forms of rehospitalization were not.

287 een baseline positive constructs and 6-month rehospitalizations were assessed via multivariable Cox r

288 l (death, heart failure hospitalization, and rehospitalization) were generated, grouping patients by

289 tes mellitus were the most common reason for rehospitalization, whereas heart failure was the most co

290 rovide accurate early detection of impending rehospitalization with a predictive accuracy comparable

291 Rehospitalization with myocardial infarction within 1 ye

292 ospital mortality, all-cause mortality or HF rehospitalization within 1 year, and in-hospital worseni

293 Rehospitalization within 30 days after an admission for

294 re than 5 days, institutional discharge, and rehospitalization within 30 days of discharge.

295 associated with 40% to 50% risk of death or rehospitalization within 6 months after discharge.

296 to 34% (P < 0.001), and RBC transfusion and rehospitalization within 6 months of hospital discharge

297 tage HCC, liver-related hospitalization, and rehospitalization within 7 and 30 days.

298 Factors associated with rehospitalization within both time periods were identifi

299 12 patients, 1326 (10.8%) had 1483 unplanned rehospitalizations within 30 days of the index event: 10

300 was the cumulative incidence of first early rehospitalization (within 30 days of discharge), and sec